Psammaplins Selectively Target Triple-Negative Metastatic Breast Tumor Cells that are Genetically Programmed to Colonize Specific Organs by Le, Thuy Phuong T.
  
 
PSAMMAPLINS SELECTIVELY TARGET TRIPLE-NEGATIVE METASTATIC 
BREAST TUMOR CELLS THAT ARE GENENETICALLY PROGRAMMED TO 
COLONIZE SPECIFIC ORGANS 
 
by  
Thuy Phuong T. Le 
 
 
A thesis submitted to the faculty of The University of Mississippi in partial fulfillment of 
the requirements of the Sally McDonnell Barksdale Honors College. 
 
 
Oxford  
May 2017 
Approved by  
___________________________________  
Advisor: Professor Yu-Dong Zhou  
___________________________________  
Reader: Professor Dale George Nagle  
___________________________________  
Reader: Professor Joseph Rhea Gladden   
 
	 ii	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017  
Thuy Phuong T. Le  
ALL RIGHTS RESERVED 
	 iii	
 
 
 
 
 
 
 
ACKNOWLEDGMENTS 
 
 
First of all, I would like to thank Dr. Yu-Dong Zhou and Dr. Dale G. Nagle for listening 
to my research interests and allowing me to bring them to life. Thank you Dr. Zhou for 
her expertise, guidance, and support in advising this project. Dr. Zhou was there for me to 
ease all of my worries throughout this stressful process, and I will forever be grateful for 
her. Thank you Dr. Nagle for being my second reader and providing me edits for my 
thesis. Also, thank you to Dr. Nagle’s research group for allowing me to contribute to 
their project. 
 
I would like to give my thanks to Dr. Joseph R. Gladden for serving as my third reader 
and expressing interest in my thesis. 
I would also like to thank the Sally McDonnel Barksdale Honors College, especially Dr. 
John Samonds, for supporting my career goals and providing me with opportunities that 
helped me get closer to achieving them.  
Finally, I want to express my sincere gratitude to my family, Michelle Ha, and Amber Vu 
for providing me with immense support and encouragement throughout my time at the 
University of Mississippi and through the process of researching and writing this thesis.   
 
 
 
 
 
 
 
 
	 iv	
 
 
 
ABSTRACT  
THUY PHUONG THI LE: Psammaplins Selectively Target Triple-Negative Metastatic 
Breast Tumor Cells that are Genetically Programmed to Colonize Specific Organs 
(Under the direction of Dr. Yu-Dong Zhou) 
 
 
Five bromotyrosine-derived marine sponge metabolites, four psammaplins (1 – 4) and the 
psammaplin dimer, bisaprasin (5) were isolated from a lipid extract sample of the marine 
sponge Dendrilla lacunosa.  Psammaplins act as histone deacetylase (HDAC) inhibitors 
that alter cellular gene expression.  The D. lacunosa psammaplins activated the oxygen 
regulated transcription factor HIF-1 (hypoxia-inducible factor-1) in T47D human breast 
tumor cells and displayed cell line specific effects against aggressive organotropic 
metastatic cell lines that were derived from triple-negative MDA-MB-231 human breast 
tumor cells. 
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Chapter 1 
Introduction 
 
Thuy Phuong T. Le 
 
1.1 Breast Cancer Background 
Aside from skin cancers, breast cancer is the most prevalent cancer among women in 
the United States. Breast cancer affects about one in eight women, and there are varying 
factors including socioeconomic status, age, race/ethnicity, and geography1. Breast 
cancer is characterized by a mass of cells that originates in the tissues of the breast, and 
there are many processes involved leading up to its eventual diagnosis2. Six processes 
have been described as the hallmarks of cancer that include: cells replicating 
uncontrollably, masses of cells creating capillary networks, cells resisting apoptosis, 
genes mutating to increase proliferation signals, cells dodging the effects of tumor 
suppressors, and cells invading into other tissues3.  
 According to the American Cancer Society (2017), the prevalence of breast 
cancer has caused scientists to develop various treatment options4. In historical terms, 
treatment options have transitioned from surgical removal to “precision medicine.” 
Depending on the localization or stage of the breast cancer, treatment options may vary. 
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For localized early stage breast cancer, surgery with a combination of radiation therapy is 
often used. It is common that a surgical option is combined with other alternatives. In 
more advanced breast cancer that has metastasized, the patient may be treated with 
hormone therapy, chemotherapy, or targeted therapy4. Targeted drugs that are currently 
being used to treat breast cancer can work through multiple mechanisms: monoclonal 
antibody (Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine), kinase inhibitor 
(Lapatinib), estrogen receptor blockers (Tamoxifen, Fulvestrant), and aromatase 
inhibitors (Letrozole, Anastrozole, and Examestane)4. The impact of these molecular-
targeted drugs has been significant, but their use is often not sufficient for complete 
cures. The multiple hit hypothesis may explain for the resistance of tumor cells to 
treatment or for reoccurring tumors5.  
1.2 Metastasis 
Unfortunately, metastasis is common in most cancers and contributes to 90% of 
breast cancer deaths. Metastasis occurs when the tumor cells become abnormally 
invasive, and metastasis is characterized by decreased cell-to-cell adhesion, decreased 
cell-matrix, digestion of underlying matrix, and transition into a “migratory” phenotype6. 
Another name for metastatic breast cancer is stage IV breast cancer or systemic breast 
cancer. Metastatic tumors commonly travel to organs that are permissive such as the 
bone, liver, lung, and brain. For breast cancer, tumor cells tend to metastasize to the 
bones, brain, and lung. Almost eighty percent of metastatic breast cancer becomes bone 
metastasis7. Brain metastases takes second place as the most common site for metastatic 
breast cancer, between 20% and 40%8. Because of the invasiveness of metastatic tumors, 
they are extremely difficult to treat and control.  
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1.3 HDAC inhibitors 
Histone deacetylases (HDACs) regulate transcription by removing acetyl groups 
from the lysine residues of histones and making a gene inactive for expression. HDACs 
have been associated with a large number of oncogenes and tumor-suppressor genes, and 
they play a role in developing malignant tumors9,10. The majority of HDACs are 
categorized into two main classes, class I HDACs and class II HDACs. Class I HDACs 
are localized specifically in the nucleus, while class II HDACs are able to move in and 
out of the nucleus to the cytoplasm. Class I HDACs consists of HDAC 1, 2, 3, and 8, 
while class II HDACs has HDAC 4, 5, 6, 7, 9a, 9b, 9c, and 10. More recently, a new class 
of HDACs (class III HDACs) have been characterized that includes the HDACs, called 
Sirtuins or SIRT1-7, that are localized in the nucleus, cytoplasm, and mitochondria. 
HDAC 11 has been recently detected and is not classified as Class IV HDACs11.  
Several HDACs inhibit the function of the p53 tumor-suppressor gene, which 
contributes to the growth of many tumors12,14. An overexpression of HDACs have been 
used as one of the biomarkers for many cancers including prostate, breast and colon 
cancer. HDAC inhibitors (HDIs) have the potential to serve as possible therapeutic 
options for various cancers by reversing HDAC-mediated gene suppression. With the 
various families of HDACs, HDAC inhibitors are structurally classified into four groups 
that include hydroxamates, cyclic peptides, alipathic acids, and benzamides12,13.  
The HDIs function by inducing apoptosis, cell cycle arrest, and differentiation in 
tumor cells, and halting the transformation of normal cells into cancer cell. Vorinostat, 
Romidepsin, and Panobinostat are HDIs currently used clinically. Vorinostat or 
suberoylanilide hydroxamic acid (SAHA) (Figure 1) is a drug that falls into the 
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hydroxomate category of HDAC inhibitors15. SAHA is a pan-selective inhibitor (IC50 10 
nM) that targets Class I and Class II HDACs16,19. The FDA-approved drug Vorinostat is 
currently prescribed to those who are affected by cutaneous T-cell lymphoma (CTCL) to 
stimulate cancer cell apoptosis17. The combination of carfilzomib, a proteasome inhibitor, 
and Vorinostat produces a dramatic antitumor effect in a xenograft model and human 
primary T-cell lymphoma cells, and the combination is currently in various phase I 
clinical trials18. Even though Vorinostat has a promising future in pharmacology, it 
produces a significant number of side effects, including diarrhea, nausea, extreme fatigue, 
hair loss, dry mouth, and muscle aches17. 
 
Figure 1. Chemical Structure of Vorinostat 
Vorinostat can bind to Zn+2 and chelate the ion in the active binding site of HDACs20,21. 
 
 Romidepsin is a FDA-approved pan-selective cyclic peptide HDAC inhibitor that 
targets Class I HDACs and is effective against CTCL. Following intravenous 
administration, romidepsin decreases the rate of cancer cell proliferation and the 
induction of the p53/p21 signaling cascades22,23. According to clincaltrials.gov on March 
21, 2017, Romidepsin inhibits both HDAC1 and HDAC2 (IC50 36 nM and 47 nM, 
respectively). Compared to other HDAC inhibitors, the potency of romidpesin is 
relatively low. Romidepsin combinations with other compounds such as oral 5-
azacitidine, cisplatin, prelatraxate, and many more are actively involved in 31 clinical 
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trials according to clinicaltrials.gov on March 26, 2016. Romedpsin side effects include 
nausea, diarrhea, constipation, changes taste, and itching24.  
 
Figure 2. Chemical Structure of Romidepsin (FK228) 
 The HDIs have shown success in stabilizing cutaneous T-cell lymphoma by 
various mechanisms that include inducing cell arrest and apoptosis. There are current 
studies that have the purpose to increase the effectiveness of FDA-approved HDIs by 
creating isoforms or pairing them with other drugs. With the discovery of the effects of 
HDIs, researchers can develop more specific approaches toward tumor HDACs. The 
HDIs also show promising potential in treating other diseases and cancers. 
1.4 Conclusions 
 With its high prevalence in women, considerable effort has been placed on the 
study of breast cancer. Many recently developed drugs do not dramatically improve long-
term survival rates. Just as with other cancers, breast cancer can progress into a fatal 
metastatic form, and it commonly does. Recently developed HDAC inhibitors have 
unique mechanisms that show great potential as new antitumor drug therapies.  
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Chapter 2 
Psammaplins Selectively Target Triple-Negative Metastatic 
Breast Tumor Cells that are Genetically Programmed to 
Colonize Specific Organs 
 
Yu-Dong Zhou, Jun Li, Lin Du, Fakhri Mahdi, Thuy Phuong T. Le, Wei-Lun Chen, 
Steven M. Swanson, and Dale G. Nagle 
*TPL performed cell viability experiments and analyzed data 
1. Introduction 
Oxygen homeostasis is considered one of the critical principles in evolution, biology, 
and medicine.  Multicellular organisms have evolved tightly regulated oxygen delivery 
systems to ensure oxygen dependent energy production.  In the human body, high levels 
of oxygen (hyperoxia) can cause oxygen toxicity and low oxygen levels (hypoxia) are 
associated with hypoxia-related diseases such as ischemic and neoplastic disorders25.  At 
the cellular level, oxygen fluctuations can trigger responses from a network of signaling 
pathways that modify the gene expression landscape26,27,28.  Master regulators of oxygen 
homeostasis, hypoxia-inducible factors (HIFs) are transcription factors that mount 
cellular responses to hypoxia at the transcription level29.  Over 100 genes have been 
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identified as HIF target genes that encode proteins involved in many aspects of cellular 
physiology, ranging from cellular metabolism, proliferation/survival/death, cytoskeletal 
structure, adhesion/motility, angiogenesis, erythropoiesis, vascular tone, stemness, to 
drug resistance30,31.  Small molecule chemicals that activate HIFs represent potential drug 
leads for hypoxia-associated diseases and chemical probes for HIF biology and oxygen 
homeostasis.  In fact, a number of HIF-1 activators [e.g., FG-2216 and FG-4592 
(FibroGen), GSK1278863 (GlaxoSmithKline), BAY85-3934 (Bayer), and AKB-6548 
(Akebia Therapeutics)] are undergoing clinical trials for preventing and alleviating 
ischemia/reperfusion injuries32,33,34.  However, most HIF-1 activators target the prolyl 
hydroxylases that regulate HIF-1α protein stability.  Given the complexity of oxygen 
homeostasis, it is a logical extension to speculate the existence of chemically diverse 
small molecules that activate HIF-1 through a wide range of pathway(s) and 
mechanism(s).  In a discovery campaign for novel natural product-derived HIF-1 
activators, lipid extracts of the sponge Dendrilla lacunosa activated HIF-1 in a T47D 
cell-based reporter assay35.  Bioassay-guided isolation and chemical structure elucidation 
afforded five bromotyrosine-derived compounds: four psammaplins and bisaprasin.  This 
study described the characterization of these compounds or HIF-1 activation-associated 
activities in cell-based in vitro models. 
Psammaplins have exhibited a range of bioactivities.  Their cytotoxic and/or 
antitumor activities have been primarily attributed to the inhibition of histone 
deacetylases (HDACs)36,37,38,39.  In this study, psammaplins were examined for the ability 
to suppress organotropic metastatic breast cancers.  Systemic metastasis-associated 
disease relapse accounts for over 90% of cancer mortality.  The five-year survival rate is 
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23% among the 162,000 American women with metastatic breast cancer40.  Breast 
cancers can metastasize to multiple organs (i.e., lung, bone, brain, liver, etc.).  Employing 
the widely studied triple-negative breast cancer (TNBC) cell line MDA-MB-231 as a 
model system, the Massagué group isolated organotropic subclones and identified 
signature gene expression profiles for lung-, bone-, and brain-specific breast cancer 
metastases41,42,43.  Employing these recently established and genetically characterized 
MDA-MB-231 derived organotropic subclones as in vitro models, psammaplins were 
examined for the ability to selectively suppress metastatic breast cancer cells in a target 
organ-dependent manner.  Psammaplins exerted more pronounced inhibitory effects 
towards the metastatic subclones specific to bone, in comparison to the others.  Herein, 
the activities of psammaplins and bisaprasin towards organotropic metastatic breast 
cancer cells are described. 
 
2. Results 
2.1. Psammaplins Exhibit Concentration-Dependent Biphasic Effects on HIF-1 
Activity 
 In a T47D cell-based reporter assay34, a lipid extract sample of the sponge 
Dendrilla lacunosa activated HIF-1 by 3.56-fold (NIH collection no. C025691, 10 µg 
mL−1).  Bioassay-guided fractionation of the extract sample (2.6 g) and chemical 
structure elucidation afforded five known compounds psammaplin E (1), (E,Z)-
psammaplin A (2), (E,E)-psammaplin K (3), (E,E)-psammaplin A (4), and bisaprasin (5).  
The structures are shown in Figure 3A.  To determine the effects of 1–5 on HIF-1 
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activity, concentration-response studies were performed in a T47D cell-based reporter 
assay (Figure 3B).  An iron chelator (1,10-phenanthroline, 10 µM) was included as a 
positive control.  Compounds 1–4 activated HIF-1 in a biphasic manner.  The highest 
level of activation was observed at the concentrations of 3 µM for 2 and 4 (12.32 ± 0.70 
and 11.01 ± 0.71 fold, respectively, n=3) and 10 µM for 1 and 3 (12.01 ± 1.12 and 10.15 
± 0.66 fold, respectively, n=3).  Compound 5 displayed weak HIF-1 activation at 30 µM 
(2.17 ± 0.13 fold, n=3).  Hypoxia (1% O2) and chemical hypoxia (iron chelators or 
transition metals) represent two common stimuli that activate HIF-144.  Further studies 
were performed to determine the effects of 1–5 on HIF-1 activity in the presence of other 
stimuli (1,10-phenanthroline, Figure 3C; hypoxia, Figure 3D).  While 1–4 acted 
synergistically with 1,10-phenanthroline and hypoxia inducing HIF-1 activity, a biphasic 
pattern of activation similar to that in the absence of stimulus (Figure 3A) was observed.  
In contrast, 5 inhibited HIF-1 activation at higher concentrations.  Previous studies 
reported that psammaplins inhibit histone deacetylase (HDAC)45.  To determine if HDAC 
inhibition non-specifically activates HIF-1, concentration-response studies were 
conducted in T47D cells transfected with the pGL3-control plasmid.  As shown in Figure 
3E, 1–4 did enhance luciferase activity in T47D cells transfected with the control 
plasmid.  However, the activation of HIF-1 was more pronounced than that of the pGL3-
control (e.g., normalized ratio of pHRE-luc/pGL3-control at 2.64 for 1 at 10 µM, 2.38 for 
2 at 3 µM, 2.38 for 3 at 10 µM, and 2.30 for 4 at 3 µM).  These observations suggest that 
1–4 activated HIF-1 with a certain degree of specificity. 
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Figure 3. Concentration-dependent biphasic effects of 1–4 on HIF-1 activation.  (A) 
Structures of psammaplins isolated from Dendrilla lacunosa.  (B) Concentration-
response results of 1–5 in T47D cells transfected with pHRE-luc for HIF-1 activity. Test 
compounds were added at the increasing concentrations of 0.1, 0.3, 1, 3, 10, and 30 µM, 
as specified. The positive control 1,10-phenanthroline (1,10-phen) was used at 10 µM. 
Data shown are average ± standard deviation (n = 3). (C) Similar to described in (B) 
except that the pHRE-luc transfected T47D cells were exposed to test compounds in the 
presence of 10 µM 1,10-phen, and the data were normalized to the positive control (1,10-
phen). (D) Similar to described in (C) except that hypoxic exposure (1% O2: 5% CO2: 
94% N2, 16 h) was applied in place of 1,10-phen. (E) As described in (B) except that 
T47D cells were transfected with the pGL3-control construct. 
D.	
pHRE-luc, Hypoxia, 16 h 
E.	
pGL3-control, 16 h 
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2.2. Differential HDAC Inhibition by Psammaplin Analogues 
 The effects of 1–5 on HDAC activity were determined in a human melanoma 
MDA-MB-435 cell-based assay. Test compounds were added at specified concentrations 
to exponentially grown cells plated in 96-well plates. After 30 min incubation, the HDAC 
activity was determined using a commercial kit (HDAC-Glo™) and normalized to that of 
the solvent control (DMSO). The standard HDAC inhibitors trichostatin A (TSA, 1 nM) 
and SAHA (100 nM) were included as positive controls. In the MDA-MB-435 cell-based 
assay, TSA and SAHA inhibited HDAC by 52% ± 8% and 60% ± 5%, respectively 
(average ± SE, n = 6). The IC50 values for 1–5 to inhibit HDAC are summarized in Table 
1. Compound 2 was the most potent HDAC inhibitor (IC50 0.019 µM), while 5 (IC50 
0.948 µM) was the least active. 
Table 1. IC50 values of 1–5 in a MDA-MB-435 cell-based HDAC assay. 
Compound IC50 (µM) 95% CI (µM)1 
1 0.257 0.157 − 0.420 
2 0.019 0.012 − 0.028 
3 0.038 0.024 − 0.061 
4 0.037 0.025 − 0.055 
5 0.948 0.586 − 1.532 
1Data from two independent experiments (n = 6) were pooled to calculate IC50. The 95% confidence interval 
(95% CI) IC50 values are also provided. 
2.3. Effects of Psammaplin A on HIF-1 Target Gene Expression 
 Over 100 genes have been identified as HIF-1 target genes that encode proteins 
involved in various aspects of cellular physiology.  While most of these genes are 
regulated in a cell type-specific manner, some are induced upon HIF-1 activation in most 
cell types.  Based on the availability and potency, compound 4 was selected for follow-up 
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studies.  The effects of 4 on the expression of HIF-1 target genes CDKN1A and VEGF 
were examined by quantitative real time RT-PCR (Figure 4).  The HIF-1 activator 1,10-
phen (10 µM) and the pan-HDAC inhibitor TSA (0.1 and 1 µM) were included as 
positive controls.  In T47D cells, 4 and TSA each increased the levels of CDKN1A 
mRNA in a concentration-dependent manner (2.9-fold for 4 at 10 µM and 7.2-fold for 
TSA at 1 µM, Figure 4A).  In contrast, neither 4 nor TSA exerted greater than 20% effect 
on the levels of VEGF mRNA (Figure 4B).  The gene VEGF encodes vascular 
endothelial growth factor (a potent angiogenic factor) and agents that inhibit VEGF are in 
clinical use for cancer46.  The expression of cellular and secreted VEGF proteins was 
examined in T47D cells by ELISA assay.  As anticipated, the positive control 1,10-phen 
induced VEGF expression at the levels of mRNA (Figure 4B), cellular protein (Figure 
4C), and secreted protein (Figure 4D).  None of the HDAC inhibitors examined (4 and 
TSA) increased VEGF protein levels at the concentrations tested (Figures 4C, 4D). 
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Figure 4. Effects of 4 and TSA on HIF-1 target gene expression. T47D cells were 
exposed to 4 and TSA at the specified concentrations for 16 h. The compound 1,10-phen 
(10 µM) was included as a positive control. The levels of CDKN1A (A) and VEGF (B) 
mRNA following treatments were determined by quantitative real time RT-PCR. Relative 
levels of target gene mRNA normalized to an internal control (18S rRNA) are shown as 
average ± standard deviation (n=3, one representative experiment). The levels of cellular 
(C) and secreted VEGF protein (D) were determined by ELISA and normalized to the 
amount of cellular proteins. Data shown are average + standard deviation (n=3). 
2.4. Psammaplins Suppress Cell Proliferation/Viability in a Cell Line-Dependent  
Manner 
 In the T47D cell-based reporter assay, psammaplins regulated HIF-1 activity in a 
biphasic manner (Figure 3).  To discern if cytotoxicity contributed to the drop in HIF-1 
activity at higher concentrations, the effects of psammaplins on cell proliferation/viability 
were examined in a panel of established human breast cancer cell lines.  The protein 
synthesis inhibitor cycloheximide (CHX, 10 µM) was used as a positive control and the 
pan-HDAC inhibitor TSA was included for comparison.  Following 48 h of compound 
treatment, all compounds affected cell proliferation/viability to a certain extent.  Among 
the psammaplins, the potency rank of 2 and 4 > 3 > 1 > 5 mirrored that observed in the 
HDAC assay (Table 1).  Greater inhibitory activity was observed in the triple negative 
breast cancer (TNBC) MDA-MB-231, MDA-MB-231-derived bone metastatic BoM1833 
(BoM) and lung metastatic LM4175 (LM) subclones, and the estrogen-dependent T47D 
cells, in comparison to the MDA-MB-231-derived brain metastatic subclone BrM-2a 
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(BrM) (Figure 5).  Similar cell line-dependent inhibitory activity was observed with TSA 
(Figure 5). 
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Figure 5. Concentration-response results of 1–5 and TSA on cell proliferation/ 
viability.  T47D (A), MDA-MB-231 (B), LM (C), BoM (D), and BrM (E) cells were 
exposed to 1–5 at the concentrations of 1, 3, 10, and 30 µM, TSA at 0.01, 0.03, 0.1, 0.3, 
and 1 µM, and CHX at 10 µM. After 48 h, cell viability was determined and presented as 
“% Inhibition” of the media control. Data shown are average + standard deviation, pooled 
from two experiments each performed in duplicate. 
 
 The effects of psammaplins on the colony-forming ability of single cells were 
assessed in a clonogenic assay. Cells seeded at low density were exposed to test 
compounds at the specified concentrations for 24 h. The conditioned media were replaced 
with growth media and the colonies formed from single cells in 14 days. While the cell 
lines differ in their colony-forming abilities, the positive control paclitaxel blocked 
colony formation in all cell lines (Figure 6). Less pronounced colony-suppressing activity 
was observed with the HDAC inhibitors. 
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Figure 6. Effects of 1–5 and TSA on colony formation.  Cells plated at low density 
were exposed to compounds (24 h) at specified concentrations (1 µM for paclitaxel and 
TSA, and 10 µM for 1–5). Two weeks later, the cells were fixed and stained. 
2.5. Psammaplin A and TSA Inhibit Tumor Cell Invasion 
 In order to form metastatic lesions, metastasis-initiating tumor cells must invade 
and intravasate into the lymphatic vasculature and/or blood vessels.  Psammaplins were 
evaluated in a Cultrex® 3-D cell invasion assay that monitors the invasion and migration 
of tumor cells grown as spheroids, which closely model in vivo pathophysiological 
conditions.  The bone metastatic BoM subclone displayed the most aggressive behavior 
(a network of extensive projections from the spheroid, Figure 7).  Compound 4 and TSA 
each inhibited the invasion of BoM spheroids into the extracellular matrix (ECM), similar 
to those observed in the presence of the positive controls paclitaxel and CHX (Figure 7).  
Furthermore, a more pronounced decrease in the size of the spheroids was observed in 
the presence of paclitaxel and CHX, in comparison to the HDAC inhibitors. 
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Figure 7. Inhibition of bone metastatic BoM cell invasion.  Tumor cell spheroids 
formed in a special spheroid formation ECM were embedded in an invasion matrix 
containing 10% FBS in the presence and absence of compounds at the specified 
concentrations.  Four days later (T96), cell invasion was recorded microscopically (the bar 
at the bottom right represents 100 µm). 
3. Discussion 
 Prevention and improved therapies have produced a steady decline in cancer rates 
in developed countries47.  In spite of this success, systemic metastasis-associated disease 
relapse accounts for over 90% of cancer mortality.  Targeted therapies have limited 
success in stalling cancer progression and improving overall survival.  Even highly 
responsive tumors often develop resistance by acquiring new mutations or by activating 
complimentary signaling pathways within a few months of treatment.  Currently, there is 
still no treatment option that effectively curbs the spread of cancers to vital organs48,49. 
 The century-old “seed and soil” hypothesis of cancer metastasis compares 
systemically distributed tumor cells to “seeds,” and selected organs colonized by 
disseminated tumor cells as “soil.”  Metastasis-initiating tumor cells invade and 
intravasate into the lymphatic vasculature and/or blood vessels, survive the circulation, 
extravasate to distant target organs, adapt to the new environment, and progress from 
dormancy to outgrowth into secondary lesions48.  The inherent complexity of metastatic 
disease and technological limitations has hindered our molecular level understanding of 
metastasis and, subsequently, the discovery of antimetastatic agents.  Treatment options 
for metastatic breast cancer include surgery, radiation, chemotherapy, hormones, and 
molecular-targeted therapies.  Since the landmark approval of trastuzumab in 1998, 
	 19	
targeted therapies that include monoclonal antibodies, tyrosine kinase inhibitors, and 
PARP inhibitors have been approved for metastatic breast cancer49.  There are >80 
ongoing targeted therapy-based clinical studies.  However, the majority of agents in 
Phase II and III clinical trials assess secondary indications for previously approved 
therapeutic agents.  Although targeted therapies can improve overall survival, few 
options exist for metastatic cancer and curative outcomes are negligible.  Metastatic 
disease remains a major cancer treatment challenge that warrants a more specific drug 
discovery approach. 
 As heterogeneous populations, tumor cells vary significantly in gene expression 
patterns, differentiation status, and malignant potential.  Genetic alterations and tumor-
microenvironment interactions affect both metastatic propensity and organ tropism50.  
Metastatic organotropism represents an innovative antimetastatic target.  Massagué and 
colleagues revolutionized the field of metastasis research by establishing the gene 
signatures associated with organotropic metastatic breast cancers41,42,43.  The discovery 
that psammaplins selectively suppressed bone metastatic breast cancer cells opens a new 
arena to explore psammaplins’ antitumor activities.  Given the fact that a number of 
HDAC inhibitors are in clinical use for cancer, the next stage will be evaluating the 
potential of HDAC inhibitors for metastatic disease. 
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4. Materials and Methods 
4.1. General Experimental Procedures 
 Routine procedures for natural product chemistry are the same as those previously 
described51. 
4.2. Sponge Material, Extract Preparation, and Bioassay-Guided Isolation 
 The sponge material was part of the NCI Open Repository Collection. Voucher 
specimens of Dendrilla lacunosa were placed on file with the Department of Invertebrate 
Zoology, National Museum of Natural History, Smithsonian Institution, Washington, DC.  
After freezing at −20 °C, the D. lacunosa sponge sample was ground in a meat grinder, 
extracted with water, the residual sample lyophilized and extracted with 50% MeOH in 
CH2Cl252.  The solvents were later removed under vacuum and the extract sample stored 
at −20 °C (NCI repository, Frederick Cancer Research and Development Center, 
Frederick, MD).  
 The D. lacunosa extract activated HIF-1 in a T47D cell-based reporter assay 
(3.56-fold at 10 µg mL-1).  A sample of 2.6 g was suspended in 50% MeOH in CH2Cl2, 
filtered to remove residue, and separated into eight fractions by Sephadex LH-20 column 
(eluted with CH2Cl2/MeOH, 50:50).  The sixth fraction (HIF-1 activation by 2.97-fold, 
1.0 µg mL−1, 285 mg) was separated by a semi-preparative HPLC [Luna 5 µm, C18(2) 
100 Å, 250 × 10.0 mm, isocratic 63% MeOH in H2O, 4.0 mL min-1], to produce 
psammaplin E (1, 0.8 mg, 0.03% yield, tR 6.1 min), (E,Z)-psammaplin A (2, 1.8 mg, , 
0.07% yield, tR 10.3 min), (E,E)-psammaplin K (3, 20 mg, , 0.76% yield, tR 11.3 min) 
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and (E,E)-psammaplin A (4, 155 mg, 5.92% yield, tR 14.3 min).  The MeOH eluate from 
HPLC column was purified by semi-preparative HPLC [Luna 5 µm, C18(2) 100 Å, 250 
× 10.0 mm, isocratic 70% MeOH in 0.1%TFA/H2O, 4.0 mL min-1], to afford bisaprasin 
(5, 6.7 mg, 0.25% yield, tR 18.2 min). 
4.3. Structural Data 
 psammaplin E (1): oil, positive ion ESI-MS, m/z 479.0/481.0 [M + H]+, m/z 
501.0/503.0 [M + Na]+; 1H NMR (CDCl3, 400 MHz): δ 7.37 (1H, d, J = 2.0 Hz, H-9), 
7.08 (1H, dd, J = 8.0, 2.0 Hz, H-13), 6.77 (1H, d, J = 8.0 Hz, H-12), 3.80 (2H, s, H-7), 
3.56 (4H, m, H-3,3’), 2.86 (4H, t, J = 6.8 Hz, H-2,2’)53.  
 (E,Z)-psammaplin A (2): gum, positive ion ESI-MS, m/z 663.0/665.0/667.0 [M + 
H]+, m/z 684.9/686.9/688.9 [M + Na]+; 1H NMR (CD3OD, 400 MHz): δ 7.37 (1H, d, J = 
2.0 Hz, H-9), 7.32 (1H, d, J = 2.0 Hz, H-9’), 7.07 (1H, dd, J = 8.0, 2.0 Hz, H-13’), 7.02 
(1H, dd, J = 8.0, 2.0 Hz, H-13), 6.79 (1H, d, J = 8.0 Hz, H-12), 6.77 (1H, d, J = 8.0 Hz, 
H-12’), 3.80 (2H, s, H-7), 3.59 (2H, s, H-7’), 3.52 (2H, t, J = 6.8 Hz, H-3), 3.50 (2H, t, J 
= 6.8 Hz, H-3’), 2.79 (2H, t, J = 7.0 Hz, H-2), 2.72 (2H, t, J = 7.0 Hz, H-2’); 13C NMR 
(CD3OD, 100 MHz): δ 164.5 (C-5’), 163.0 (C-5), 152.9 (C-6’), 152.4 (C-6), 151.7 (C-11) 
151.4 (C-11’), 133.1 (C-9, 9’), 129.1 (C-13’), 129.0 (C-13), 128.9 (C-8), 128.7 (C-8’), 
115.8 (C-12) 115.7 (C-12’), 109.4 (C-10), 109.1 (C-10’), 38.2 (C-3’), 37.9 (C-3), 37.0 
(C-2, 2’), 36.8 (C-7’), 27.3 (C-7)54.  
 (E,E)-psammaplin K (3): gum, positive ion ESI-MS, m/z 679.0/681.0/683.0 [M 
+ H]+, m/z 700.9/702.9/704.9 [M + Na]+;  1H NMR (CDCl3, 400 MHz): δ 7.36 (1H, br s, 
H-9), 7.06 (1H, d, J = 7.2 Hz, H-13), 6.85 (1H, s, H-9’), 6.75 (1H, d, J = 8.0 Hz, H-12), 
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6.71 (1H, s, H-13’), 3.79 (2H, s, H-7’), 3.73 (2H, s, H-7), 3.51 (4H, t, J = 6.8 Hz, H-3, 
3’), 2.80 (4H, t, J = 6.8 Hz, H-2, 2’); 13C NMR (CDCl3, 100 MHz): δ 164.5 (C-5, 5’), 
152.3 (C-6), 151.7 (C-11, 6’), 145.7(C-12’), 141.1 (C-11’), 133.1(C-9), 129.2 (C-13), 
129.0 (C-8, 8’), 123.4 (C-9’), 115.6 (C-12), 115.0 (C-13’), 109.1 (C-10, 10’), 38.2 (C-3, 
3’), 37.1 (C-2, 2’), 27.5 (C-7’), 27.3 (C-7)55.  
 (E,E)-psammaplin A (4): white powder, positive ion ESI-MS, m/z 
663.0/665.0/667.0 [M + H]+, m/z 684.9/686.9/688.9 [M + Na]+; 1H NMR (CD3OD, 400 
MHz): δ 7.36 (2H, d, J = 2.0 Hz, H-9, 9’), 7.06 (2H, dd, J = 8.4, 2.0 Hz, H-13, 13’), 6.75 
(2H, d, J = 8.4 Hz, H-12, 12’), 3.79 (4H, s, H-7, 7’), 3.51 (4H, t, J = 6.8 Hz, H-3, 3’), 
2.79 (4H, t, J = 6.8 Hz, H-2, 2’); 13C NMR (CD3OD, 100 MHz): δ 164.5 (C-5, 5’), 152.3 
(C-6, 6’), 151.7 (C-11, 11’), 133.1 (C-9, 9’), 129.2 (C-13, 13’), 129.0 (C-8, 8’), 115.6 (C-
12, 12’), 109.1 (C-10, 10’), 38.2 (C-3, 3’), 37.1 (C-2, 2’), 27.3 (C-7, 7’)55.  
 Bisaprasin (5): gum, negative ion ESI-MS, m/z 660.9/661.9/662.9 [M – 2H]2-; 1H 
NMR (CD3OD, 400 MHz): δ 7.42 (2H, br s, H-9’’, 9’’’), 7.37 (2H, br s, H-9, 9’), 7.06 
(4H, m, H-13, 13’, 13’’, 13’’’), 6.77 (1H, m, H-12, 12’), 3.85 (4H, s, H-7’’,7’’), 3.79 (4H, 
s, H-7, 7’), 3.52 (8H, m, H-3, 3’, 3’’, 3’’’), 2.79 (8H, m, H-2, 2’, 2’’, 2’’’); 13C NMR 
(CD3OD, 100 MHz): δ 164.5 (C-5, 5’, 5’’, 5’’’), 152.3 (C-11, 11’), 151.7 (C-6,6’), 151.6 
(C-6’’,6’’’), 149.2 (C-11’’, 11’’’), 133.1 (C-9, 9’), 132.6 (C-9’’, 9’’’), 131.2 (C-13, 13’), 
129.7 (C-8), 129.2 (C-8’), 129.0 (C-13’’, 13’’’), 127.2 (C-8’’, 8’’’), 115.7 (C-12, 12’), 
111.6 (C-12’’, 12’’’), 109.1 (C-10, 10’, 10’’, 10’’’), 38.2 (C-3, 3’, 3’’, 3’’’), 37.1 (C-2, 
2’, 2’’, 2’’’), 27.4 (C-7’’, 7’’’), 27.3 (C-7, 7’)55,56. 
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4.4. T47D Cell-Based Reporter Assay 
 Human breast cancer T47D cells (ATCC, Manassas, VA) were maintained in 
DMEM/F12 medium with L-glutamine (Corning, Corning, NY), supplemented with 10% 
(v/v) fetal bovine serum (FBS, Hyclone, Logan, Utah), 50 units mL−1 penicillin and 50 
µg mL−1 streptomycin (Thermo Fisher Scientific, Waltham, MA). To monitor HIF-1 
activity, T47D cells were transfected with the pHRE3-TK-Luc construct and the cell-
based luciferase reporter assay performed as described35. Cells were exposed to test 
compounds in the absence (pHRE-luc) and presence (pHRE-luc, 1,10-phen) of 1,10-
phenanthroline (10 µM), or hypoxic conditions (1% O2: 5% CO2: 94% N2) (pHRE-luc, 
Hypoxia) for 16 h. For the control cell-based reporter assay, T47D cells were transfected 
with the pGL3-control construct (Promega, Madison, WI), exposed to test compounds for 
16 h, and the luciferase reporter assay performed as described35. Unless specified, all 
compounds were purchased from Sigma (St. Louis, MO). 
4.5. MDA-MB-435 Cell-Based HDAC Assay 
 Human melanoma MDA-MB-435 cells were maintained in RPMI 1640 medium 
supplemented with 10% FBS, 100 units mL−1 penicillin and 100 µg mL−1 streptomycin. 
Exponentially grown cells were seeded at the density of 5000 cells/well into 96-well 
plates (Corning, Corning, NY) and incubated overnight. Compounds dissolved in DMSO 
were added to achieve the specified final concentrations (total volume: 100 µL, DMSO: 
0.5%). The incubation continued for 30 min at 37 °C and the HDAC activity determined 
using a commercial luminescent assay (HDAC-Glo™, Promega Corp, Madison, WI) 
following manufacturer's instructions. The HDAC inhibitors trichostatin A (TSA, 1 nM) 
	 24	
and SAHA (100nM) were used as positive controls and the data presented as percentage 
inhibition of the solvent control. 
4.6. Quantitative Real-Time RT-PCR and ELISA Assay 
 The effects of test samples on HIF-1 target gene expression were assessed in 
T47D cells. To determine the levels of CDKN1A and VEGF mRNA, quantitative real-
time RT-PCR was performed as described: 1) cell plating, compound treatment, and total 
RNA extraction57; and 2) first strand cDNA synthesis, gene-specific primer sequences, 
quantitative real time PCR, and data analysis58. To determine the levels of cellular and 
secreted VEGF proteins, T47D cells were exposed to compounds as described58, the 
levels of VEGF proteins in the conditioned medium and cell lysate samples determined 
by ELISA35, the amount of proteins in the cell lysate samples quantified using a micro 
BCA assay kit (Thermo Fisher Scientific, Rockford, IL), and the levels of VEGF proteins 
normalized to that of cellular proteins. 
4.7. Cell Proliferation/Viability and Clonogenic Survival Assays 
 Human breast cancer T47D, MDA-MB-231, and the MDA-MB-231-derived 
subclones BoM1833, LM4175, and BrM-2a (J. Massagué, Memorial Sloan Kettering 
Cancer Center, New York, NY) were maintained in RPMI 1640 medium supplemented 
with 10% FBS, 50 units mL−1 penicillin and 50 µg mL−1 streptomycin. The cell 
proliferation/viability assay (48 h exposure) was performed as described59. Cell viability 
was determined by the sulforhodamine B method and the data presented as '% Inhibition' 
of the media control. 
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 For the clonogenic assay, exponentially grown cells were seeded at the density of 
1,000 cells/well into 6-well plates (Cellstar®, Greiner Bio-One GmbH, Austria) and 
incubated at 37° C for 4 h to allow the cells to adhere. Compound addition was similar as 
above. After 24 h, the compound-containing conditioned media were replaced with fresh 
RPMI 1640 medium containing FBS (10%) and P/S.  The incubation continued for 
another 14 days with a change of medium every 5 days, the cells were fixed with 
methanol and stained with crystal violet (1 mg mL−1 in 20% ethanol), and the images 
were acquired with a Kodak digital camera. 
4.8. 3D Tumor Cell Invasion Assay 
 A commercial kit (Cultrex® 3D Spheroid Cell Invasion Assay) was used to 
perform this assay, following the manufacturer’s instructions (Trevigen, Gaithersburg, 
MD). 
4.9. Statistic Analysis 
 Data comparison was performed with one-way ANOVA followed by Bonferroni 
post hoc analyses using GraphPad Prism 6. Differences between datasets were considered 
statistically significant when p < 0.05. 
 
 
 
 
	 26	
LIST OF REFERENCES 
1. Ma, J., & Jemal, A. (2013). Breast cancer statistics. In Breast Cancer Metastasis and 
Drug Resistance (pp. 1-18). Springer New York. 
2. Key, T. J., Verkasalo, P. K., & Banks, E. (2001). Epidemiology of breast cancer. The 
lancet oncology, 2(3), 133-140. 
3. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. cell, 100(1), 57-70. 
4. American Cancer Society (2017). Breast Cancer Treatment. Retrieved April 6, 2017, 
from https://www.cancer.org/cancer/breast-cancer/treatment.html 
5. Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007). 
Overview of resistance to systemic therapy in patients with breast cancer. In Breast 
Cancer Chemosensitivity (pp. 1-22). Springer New York. 
6. Moh, M. C., & Shen, S. (2009). The roles of cell adhesion molecules in tumor 
suppression and cell migration: A new paradox. Cell Adhesion & Migration, 3(4), 
334–336. 
7. Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., De Boer, R. H., ... 
& Fan, M. (2010). Denosumab compared with zoledronic acid for the treatment of 
bone metastases in patients with advanced breast cancer: a randomized, double-blind 
study. Journal of Clinical Oncology, 28(35), 5132-5139. 
8. Weil, R. J., Palmieri, D. C., Bronder, J. L., Stark, A. M., & Steeg, P. S. (2005). Breast 
cancer metastasis to the central nervous system. The American journal of pathology, 
167(4), 913-920. 
9. Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015). Histone Deacetylase 
Inhibitors in Clinical Studies as Templates for New Anticancer Agents. Molecules, 
20(3), 3898-3941. doi:10.3390/molecules20033898 
10. Nelson, D. L., Nelson, D. L., Lehninger, A. L., & Cox, M. M. (2008). Lehninger 
Principles of Biochemistry. New York: W.H. Freeman. 
11. Ruijter, A. J., Gennip, A. H., Caron, H. N., Kemp, S., & Kuilenburg, A. B. (2003). 
Histone  
deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J.  
Biochemical Journal, 370(3), 737-749. doi:10.1042/bj20021321 
12. Ahmadzadeh, A., Khodadi, E., Shahjahani, M., Bertacchini, J., Vosoughi, T., & Saki, 
N. (2015). The Role of HDACs as Leukemia Therapy Targets using HDI. 
International Journal of Hematology-Oncology and Stem Cell Research, 9(4), 203–
214 
13. Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L., Martin, B. P., … 
Johnstone, R. W.  
(2013). HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional  
responses. Cell Death & Disease, 4(2), e519–. http://doi.org/10.1038/cddis.2013.9 
14. Zhang, Z. (2004). HDAC6 Expression Is Correlated with Better Survival in Breast 
Cancer. Clinical Cancer Research, 10(20), 6962-6968. doi:10.1158/1078-0432.ccr-
04-0455 
15. Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & 
Richon, V. M.  
(2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-
regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings 
	 27	
of the National Academy of Sciences of the United States of America, 99(18), 11700–
11705. http://doi.org/10.1073/pnas.182372299 
16. Belvedere, S., Witter, D. J., Yan, J., Secrist, J. P., Richon, V., & Miller, T. A. (2007).  
Aminosuberoyl hydroxamic acids (ASHAs): A potent new class of HDAC inhibitors. 
Bioorganic & Medicinal Chemistry Letters, 17(14), 3969-3971. 
doi:10.1016/j.bmcl.2007.04.089 
17. Vorinostat: Medline Plus Drug Information. (2009, February 1). Retrieved May 5, 
2016, from  
https://www.nlm.nih.gov/medlineplus/druginfo/meds/a607050.html 
18. Gao, M., Chen, G., Wang, H., Xie, B., Hu, L., Kong, Y., . . . Shi, J. (2014). 
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-
cell leukemia/lymphoma. Oncotarget. doi:10.18632/oncotarget.8667 
19. Vorinostat (SAHA, MK0683). (2013). Retrieved May 06, 2016, from  
http://www.selleckchem.com/products/Vorinostat-saha.html 
20. Praseetha, S., Bandaru, S., Nayarisseri, A., & Sureshkumar, S. (2016). 
Pharmacological  
Analysis of Vorinostat Analogues as Potential Anti-tumor Agents Targeting Human 
Histone Deacetylases: An Epigenetic Treatment Stratagem for Cancers. Asian Pacific 
Journal of Cancer Prevention. http://dx.doi.org/10.7314/APJCP.2016.17.3.157z 
21. Marks, P. A. (2007). Discovery and development of SAHA as an anticancer agent. 
Oncogene, 26(9), 1351-1356. doi:10.1038/sj.onc.1210204 
22. Romidepsin Injection: Medline Plus Drug Information. (2009, February 1). Retrieved 
May 5, 2016, from 
https://www.nlm.nih.gov/medlineplus/druginfo/meds/a610005.html 
23. Li, L., Zhang, P., Cai, P., & Li, Z. (2016). Original article: Histone deacetylase 
inhibitor,  
Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation 
of p53-p21 pathway. Biomedicine & Pharmacotherapy, 
doi:10.1016/j.biopha.2016.04.053 
24. Romidepsin (FK228, Depsipeptide). (2013). Retrieved May 06, 2016, from  
http://www.selleckchem.com/products/Romidepsin-FK228.html 
25. Patel PM, Patel HH, Roth DM (2011) General Anesthetics and Therapeutic Gases. 
Chapter 19 in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 
12th Edition, Brunton LL, Chabner BA, Knollman BC, Ed., pp. 527-564.  McGraw 
Hill Medical. 
26. Michiels C (2004) Physiological and pathological responses to hypoxia. Am J Pathol 
164, 1875-1882. 
27. Nallamshetty S, Chan SY, Loscalzo J (2013) Hypoxia: a master regulator of 
microRNA biogenesis and activity. Free Radic Biol Med 64, 20-30. 
28. Span PN, Bussink J (2015) Biology of hypoxia. Semin Nucl Med 45, 101-109. 
29. Semenza GL (2014) Oxygen sensing, hypoxia-inducible factors, and disease 
pathophysiology. Annu Rev Pathol 9, 47-71. 
30. Keith B, Johnson RS, Simon MC (2012) HIF1α and HIF2α: sibling rivalry in hypoxic 
tumour growth and progression. Nat Rev Cancer 12, 9-22. 
31. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and 
targets for cancer therapy. Trends Pharmacol Sci 33, 207-214. 
	 28	
32. Bouchie A (2013) First-in-class anemia drug takes aim at Amgen's dominion. Nat 
Biotechnol 31, 948-949. 
33. Forristal CE, Levesque JP (2014) Targeting the hypoxia-sensing pathway in clinical 
hematology. Stem Cells Transl Med 3, 135-140. 
34. Rabinowitz MH (2013) Inhibition of hypoxia-inducible factor prolyl hydroxylase 
domain oxygen sensors: tricking the body into mounting orchestrated survival and 
repair responses. J Med Chem 56, 9369-9402. 
35. Hodges TW, Hossain CF, Kim YP, Zhou YD, Nagle DG. (2004). J Nat Prod. 67:767–
771. 
36. Hong S, Shin Y, Jung M, Ha MW, Park Y, Lee YJ, Shin J, Oh KB, Lee SK, Park HG 
(2015) Efficient synthesis and biological activity of Psammaplin A and its analogues 
as antitumor agents. Eur J Med Chem 96, 218-230. 
37. Kim TH, Kim HS, Kang YJ, Yoon S, Lee J, Choi WS, Jung JH, Kim HS (2015) 
Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-
resistant MCF-7/adr human breast cancer cells and xenografts. Biochim Biophys Acta 
1850, 401-410. 
38. Ahn MY, Jung JH, Na YJ, Kim HS (2008) A natural histone deacetylase inhibitor, 
Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer 
cells. Gynecol Oncol 108, 27-33. 
39. Mora FD, Jones DK, Desai PV, Patny A, Avery MA, Feller DR, Smillie T, Zhou YD, 
Nagle DG (2006) Bioassay for the identification of natural product-based activators 
of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine 
sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in 
human breast tumor cells. J Nat Prod 69, 547-552. 
40. American Cancer Society (2012) Breast Cancer, Facts & Figures 2011-2012 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/doc
ument/acspc-030975.pdf 
41. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, 
Massagué J (2003) A multigenic program mediating breast cancer metastasis to bone. 
Cancer Cell 3, 537-549. 
42. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, 
Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. 
Nature, 436, 518-524. 
43. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de 
Vijver MJ, Gerald WL, Foekens JA, Massagué J (2009) Genes that mediate breast 
cancer metastasis to the brain. Nature, 459, 1005-1009 
44. Nagle, D.G.; Zhou, Y.-D. "Natural product-derived small molecule activators of 
hypoxia-Inducible Factor-1 (HIF-1)" Curr. Pharm. Design 2006, 12, 2673–2688. 
45. García J, Franci G, Pereira R, Benedetti R, Nebbioso A, Rodríguez-Barrios F, 
Gronemeyer H, Altucci L, de Lera AR (2011) Epigenetic profiling of the antitumor 
natural product psammaplin A and its analogues. Bioorg Med Chem 19, 3637-3649. 
46. Ferrara N, Adamis AP (2016) Ten years of anti-vascular endothelial growth factor 
therapy. Nat Rev Drug Discov. 15(6):385-403. 
47. Cancer Research UK (2011) CancerStats, Cancer Worldwide 
http://publications.cancerresearchuk.org/downloads/product/CS_CS_WORLD.pdf. 
	 29	
48. Sethi N, Kang Y (2011) Unravelling the complexity of metastasis - molecular 
understanding and targeted therapies. Nature Reviews Cancer, 11, 735-748. 
49. Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights 
into the clinic. Nature Medicine, 19, 1450-1464. 
50. Nguyen DX, Massagué J (2007) Genetic determinants of cancer metastasis. Nature 
Reviews Genetics, 8, 341-352.   
51. Du, L., Zhou, Y. D., & Nagle, D. G. (2013). Inducers of hypoxic response: Marine 
sesquiterpene quinones activate HIF-1. Journal of natural products, 76(6), 1175. 
52. McCloud TC. Molecules. 2010; 15:4526–4563  
53. Piña, I. C., Gautschi, J. T., Wang, G. Y. S., Sanders, M. L., Schmitz, F. J., France, D., 
Cornell-Kennon S., Sambucetti L. C., Remiszewski S. W., Perez L. B., Bair, K. W. 
(2003). Psammaplins from the Sponge Pseudoceratina p urpurea: Inhibition of Both 
Histone Deacetylase and DNA Methyltransferase. The Journal of organic chemistry, 
68(10), 3866-3873.  
54. Park, Y., Liu, Y., Hong, J., Lee, C. O., Cho, H., Kim, D. K., ... & Jung, J. H. (2003). 
New Bromotyrosine Derivatives from an Association of Two Sponges, Jaspis w 
ondoensis and Poecillastra w ondoensis. Journal of natural products, 66(11), 1495-
1498.  
55. Tabudravu J.N., Eijsink V.G.H, Gooday G.W., Jaspars M., Komander D., Legg M., et 
al. (2002) Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge 
Aplysinella rhax. Bioorg. Med. Chem. 10, 1123–1128  
56. Rodríguez, A.D.; Akee, R.K.; Scheuer, P.J. (1987). Two bromotyrosine-cysteine 
derived metabolites from a sponge. Tetrahedron Lett. 28, 4989–4992.  
57. Hossain, C. F., Kim, Y. P., Baerson, S. R., Zhang, L., Bruick, R. K., Mohammed, K. 
A., ... & Zhou, Y. D. (2005). Saururus cernuus lignans—Potent small molecule 
inhibitors of hypoxia-inducible factor-1. Biochemical and biophysical research 
communications, 333(3), 1026-1033. 
58. Zhou, Y. D., Kim, Y. P., Li, X. C., Baerson, S. R., Agarwal, A. K., Hodges, T. W., ... 
& Nagle, D. G. (2004). Hypoxia-inducible factor-1 activation by (−)-epicatechin 
gallate: potential adverse effects of cancer chemoprevention with high-dose green tea 
extracts. Journal of natural products, 67(12), 2063-2069. 
59. Liu, Y., Veena, C. K., Morgan, J. B., Mohammed, K. A., Jekabsons, M. B., Nagle, D. 
G., & Zhou, Y. D. (2009). Methylalpinumisoflavone inhibits hypoxia-inducible 
factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. Journal of 
Biological Chemistry, 284(9), 5859-5868. 
 
 
 
 
 
